<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; GenVec Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/genvec-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(GNVC) Stock Market News for December 30, 2010 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2010/12/30/gnvc-stock-market-news-for-december-30-2010-market-news/64196</link>
		<comments>http://www.stockbloghub.com/2010/12/30/gnvc-stock-market-news-for-december-30-2010-market-news/64196#comments</comments>
		<pubDate>Thu, 30 Dec 2010 15:47:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GenVec Inc]]></category>
		<category><![CDATA[GNVC]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[NBL]]></category>
		<category><![CDATA[Noble Energy Inc]]></category>
		<category><![CDATA[Occidental Petroleum Corporation]]></category>
		<category><![CDATA[OXY]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Schlumberger Limited]]></category>
		<category><![CDATA[Sears Holdings Corporation]]></category>
		<category><![CDATA[SHLD]]></category>
		<category><![CDATA[SLB]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Yahoo! Inc.]]></category>
		<category><![CDATA[YHOO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=64196</guid>
		<description><![CDATA[Even though the markets trimmed the intra-day rally during closing hours on Wednesday, the benchmarks still moved modestly upward to achieve new highs. After-effects of the snowstorm in the Northeast continued to keep investors away from the Street. In addition, the ongoing holiday season has kept trading volume on the thinner side, while investors wait optimistically for a fresh start next year. The Dow Jones Industrial Average was up 0.09% and closed at 11,585.38. The Standard &#38; Poor&#8217;s 500 Index rose 0.11% to close at 1,259.78. The Nasdaq Composite ended the day 0.15% higher at 2,666.93. The CBOE Volatility Index (VIX) fell to just above 17. On the New York Stock Exchange, the advance decline ratio was 2:1 and volumes were a modest 1.9 billion. Amid light volume trading, S&#38;P ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/12/30/gnvc-stock-market-news-for-december-30-2010-market-news/64196/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GNVC) GenVec Final Stage Trial Experiences Major Setback</title>
		<link>http://www.stockbloghub.com/2010/03/31/gnvc-genvec-final-stage-trial-experiences-major-setback/32382</link>
		<comments>http://www.stockbloghub.com/2010/03/31/gnvc-genvec-final-stage-trial-experiences-major-setback/32382#comments</comments>
		<pubDate>Wed, 31 Mar 2010 19:46:56 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GenVec Inc]]></category>
		<category><![CDATA[GNVC]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32382</guid>
		<description><![CDATA[In a major setback, GenVec (GNVC) had to discontinue its final stage trial of TNFerade in patients with pancreatic cancer following an interim analysis. The interim analysis was conducted to ensure if the study should be continued after the 184th death, which was two-thirds of total expected events. GenVec took this decision based on discussions with a Data Safety Monitoring Board. They came to the conclusion that the trial is unlikely to meet its goal of improving overall survival in patients. The phase III trial, conducted with 330 advanced pancreatic cancer patients, compared treatment with TNFerade (along with standard of care (SOC)) to SOC alone. It was observed that the TNFerade plus SOC arm demonstrated an 8% lower risk of death compared to SOC alone, which is not statistically significant. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/31/gnvc-genvec-final-stage-trial-experiences-major-setback/32382/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVS) Novartis Collaborates with GenVec on Hearing Loss Treatments</title>
		<link>http://www.stockbloghub.com/2010/01/20/nvs-novartis-collaborates-with-genvec-on-hearing-loss-treatments/25401</link>
		<comments>http://www.stockbloghub.com/2010/01/20/nvs-novartis-collaborates-with-genvec-on-hearing-loss-treatments/25401#comments</comments>
		<pubDate>Wed, 20 Jan 2010 18:34:07 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACL]]></category>
		<category><![CDATA[Alcon Inc]]></category>
		<category><![CDATA[GenVec Inc]]></category>
		<category><![CDATA[GNVC]]></category>
		<category><![CDATA[INCY]]></category>
		<category><![CDATA[Incyte Corporation]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25401</guid>
		<description><![CDATA[Recently, Novartis (NVS) entered into a collaboration with GenVec (GNVC) for the development of treatments for hearing loss and balance disorders. Earlier, preclinical results have found strong potential in GenVec&#8217;s adenovector technology for the restoration of hearing and balance functions. Per the agreement, Novartis has acquired worldwide rights to the program, for which it has paid $5 million upfront. GenVec is also eligible to receive up to $213.6 million in the form of milestone payments and royalties on the sale of the drug. In addition, Novartis has purchased shares of GenVec worth $2 million. It will also provide funding to GenVec for conducting research programs for the development of additional adenovectors for hearing loss. Novartis is looking at strengthening its pipeline to compensate for the loss of revenues once several ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/20/nvs-novartis-collaborates-with-genvec-on-hearing-loss-treatments/25401/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

